<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lupus nephritis: Treatment of relapsing focal or diffuse lupus nephritis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lupus nephritis: Treatment of relapsing focal or diffuse lupus nephritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lupus nephritis: Treatment of relapsing focal or diffuse lupus nephritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald J Falk, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maria Dall'Era, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerald B Appel, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brad H Rovin, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 04, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2042243210"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Up to one-third of patients with focal or diffuse lupus nephritis (LN) who initially achieve a complete response on immunosuppressive therapy will have a relapse (also called renal flare) following reduction or cessation of immunosuppression or nonadherence to oral drug therapy.</p><p>The treatment of relapsing focal or diffuse LN will be reviewed here. The treatment of focal or diffuse LN and lupus membranous nephropathy, the treatment of resistant disease, as well as issues related to end-stage LN, are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3093.html" rel="external">"Lupus nephritis: Therapy of lupus membranous nephropathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3092.html" rel="external">"Lupus nephritis: Treatment of focal or diffuse lupus nephritis resistant to initial therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3066.html" rel="external">"Kidney transplantation in adults: Issues related to lupus nephritis"</a>.)</p><p></p><p class="headingAnchor" id="H2298862913"><span class="h1">DEFINITION OF RELAPSE</span><span class="headingEndMark"> — </span>Relapse of focal or diffuse lupus nephritis (LN) following an initial response to therapy is primarily defined as recurrent inflammatory activity, usually manifested by any of the following parameters: an active urine sediment (eg, glomerular hematuria with red and/or white blood cell casts, white blood cells in the absence of infection), increased urine protein excretion, and/or an increased serum creatinine [<a href="#rid1">1-3</a>]. Relapses may occur while on immunosuppressive therapy or after reduction or discontinuation of therapy.</p><p>Disease relapse is different from resistant disease, which refers to the failure of initial immunosuppressive therapy to achieve either a complete or partial clinical response. (See  <a class="medical medical_review" href="/z/d/html/3092.html" rel="external">"Lupus nephritis: Treatment of focal or diffuse lupus nephritis resistant to initial therapy", section on 'Establishing resistant disease'</a>.)</p><p class="headingAnchor" id="H120198483"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Relapses of focal or diffuse lupus nephritis (LN) occur in as many as one-third of patients during follow-up of up to 10 years [<a href="#rid4">4-10</a>].</p><p>Risk factors for relapsing disease include intentional cessation or reduction of immunosuppression, nonadherence to oral drug regimens, more severe disease at baseline, low levels of serum C3 and high levels of anti-double-stranded DNA (anti-dsDNA), a delay in reaching a complete response, and attainment of a partial compared with complete response to initial therapy [<a href="#rid1">1,4,5,10-18</a>].</p><p class="headingAnchor" id="H1772823446"><span class="h1">ESTABLISHING RELAPSING DISEASE</span></p><p class="headingAnchor" id="H2918502005"><span class="h2">Monitoring for relapse</span><span class="headingEndMark"> — </span>Regular, indefinite follow-up and monitoring is needed for all patients with focal or diffuse lupus nephritis (LN), even for those in complete clinical remission for several years. Relapses can occur at any time during the course of LN, including during the initial treatment phase or during long-term subsequent therapy intended to lower the frequency of relapses. Monitoring during initial and subsequent therapy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Monitoring the response to therapy'</a>.)</p><p>In patients who have completed initial and subsequent therapy, we continue to monitor patients every three to four months to assess for relapse. Laboratory data obtained during follow-up visits include:</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis with examination of the freshly prepared urinary sediment</p><p class="bulletIndent1"><span class="glyph">●</span>Quantification of urine protein excretion (usually with a random spot urine protein-to-creatinine ratio, but some experts confirm changes with a 24-hour urine)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine (as well as a basic metabolic profile)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum complement levels (C3 and C4)</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-double-stranded DNA (anti-dsDNA) antibody levels</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential and platelets</p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocyte sedimentation rate and/or C-reactive protein level</p><p></p><p>Patients who have an increase in anti-dsDNA titers or new hypocomplementemia after achieving a complete response should be monitored more frequently (particularly over the ensuing three months) but are not treated for relapse <strong>solely</strong> based upon changes in serologic activity.</p><p>The rationale for serologic monitoring is based in part upon the observation that an elevation in the anti-dsDNA antibody titer and, to a lesser degree, a fall in circulating complement levels are associated with a high likelihood (over 75 percent in one report) of subsequent clinical relapse, which typically occurs within the ensuing 8 to 10 weeks [<a href="#rid19">19</a>]. Also, it has been suggested that a fall in complement levels is a more valuable predictor of subsequent relapse than is the absolute plasma concentrations, as there may be a prolonged reduction in C4 levels long after a complete response has been achieved [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/1814.html" rel="external">"Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP", section on 'Titer, pathogenicity, and disease activity'</a>.)</p><p class="headingAnchor" id="H413821990"><span class="h2">Diagnosis of relapse</span><span class="headingEndMark"> — </span>The diagnosis of a relapse of diffuse or focal LN is largely clinical and based on the presence of recurrent inflammatory activity, usually manifested by any of the following parameters: an active urine sediment (eg, glomerular hematuria with red and/or white blood cell casts, white blood cells in the absence of infection), increased urine protein excretion, and/or an increased serum creatinine in the absence of an alternative diagnosis. An increase in anti-dsDNA antibody levels and/or a decrease in serum complement levels are also supportive of a diagnosis of relapse [<a href="#rid19">19,20</a>]. All patients with suspected relapse should be evaluated for their adherence to therapy. (See  <a class="medical medical_review" href="/z/d/html/3092.html" rel="external">"Lupus nephritis: Treatment of focal or diffuse lupus nephritis resistant to initial therapy", section on 'Assessment of patient adherence to therapy'</a>.)</p><p>A kidney biopsy is frequently required to verify recurrent active LN rather than nonimmunologic progression of kidney disease or an alternative diagnosis (see  <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification", section on 'When to repeat the biopsy'</a>). Some patients with focal or diffuse LN have a proteinuric relapse, characterized by increased proteinuria (≥2 g/day increase in protein excretion over baseline) with an inactive urine sediment and a stable serum creatinine [<a href="#rid1">1,2</a>]. Repeat biopsy may be helpful since such patients may have proteinuria as a consequence of chronic scarring, active disease, or transformation to lupus membranous nephropathy. However, in patients with clinical and serologic findings consistent with active disease, a biopsy may not be necessary, particularly if the results are unlikely to alter therapy. In those patients where the clinical indicators are equivocal, a biopsy is still recommended. (See <a class="local">'Patients with concurrent lupus membranous nephropathy'</a> below.)</p><p>Estimation of the glomerular filtration rate (GFR) alone may be misleading when monitoring the course of LN that seems to be inactive. As in other kidney diseases, nephron loss in LN is associated with compensatory hypertrophy and intraglomerular hypertension in the remaining normal or less-affected glomeruli [<a href="#rid21">21</a>]. As a result, the GFR and the serum creatinine may initially remain stable, and the degree of proteinuria may fall after the resolution of active inflammation following immunosuppressive therapy [<a href="#rid21">21</a>]. However, over time, there is frequently increasing glomerulosclerosis on repeat kidney biopsy, often in the absence of clinical or serologic evidence of active systemic lupus erythematosus (SLE) [<a href="#rid21">21,22</a>]. In one study, for example, the number of sclerotic glomeruli increased from 15 to 60 percent over a three-year period despite a relatively stable GFR [<a href="#rid21">21</a>]. Both healing of previous inflammatory injury and nonimmunologic mechanisms of progression can account for these findings without requiring relapse and active disease [<a href="#rid22">22</a>].</p><p>A slowly progressive decline in GFR resulting from worsening glomerulosclerosis due to nonimmunologic mechanisms should <strong>not</strong> be treated with immunosuppressive agents. Therapy should instead be directed toward aggressive antihypertensive and antiproteinuric therapy with blockade of the renin-angiotensin system (eg, angiotensin-converting enzyme [ACE] inhibitor or angiotensin II receptor blocker [ARB]). These issues are discussed separately. A repeat kidney biopsy should be performed if there is any uncertainty about the cause of the GFR decline. (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Blood pressure goal'</a> and  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Proteinuria goal'</a> and  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'General supportive measures in all patients'</a>.)</p><p class="headingAnchor" id="H50284034"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H2071691527"><span class="h2">Approach based on disease severity</span><span class="headingEndMark"> — </span>The treatment of relapsing focal or diffuse lupus nephritis (LN) depends upon the initial immunosuppressive regimen and the severity and timing of relapse  (<a class="graphic graphic_algorithm graphicRef133201" href="/z/d/graphic/133201.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2218856737"><span class="h3">Mild relapse</span><span class="headingEndMark"> — </span>Mild relapse is defined as increased activity of urine sediment and, possibly, a modest (eg, less than 50 percent) increase in urine protein excretion but with a stable serum creatinine.</p><p>The approach to the treatment of a mild relapse depends on whether the relapse occurs while the patient is still receiving ongoing therapy  (<a class="graphic graphic_algorithm graphicRef133201" href="/z/d/graphic/133201.html" rel="external">algorithm 1</a>) (see  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Subsequent therapy'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse during therapy</strong> – For most patients who develop a mild relapse while still receiving therapy, we suggest increasing the dose of glucocorticoids and, if possible, increasing the dose of the immunosuppressive agent. As an example, in a patient receiving tapering doses of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> and <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, the prednisone dose can be increased back to 60 mg/day (although lower starting doses may be adequate), and the azathioprine can be increased to 2 mg/kg per day (to a maximum of 150 to 200 mg/day). Similarly, in a patient receiving <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF), the dose can be increased to 1500 mg twice a day if tolerated. (See  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Dosing and duration of subsequent therapy'</a>.)</p><p></p><p class="bulletIndent1">However, for those who cannot easily increase the doses of their original immunosuppressive regimen (eg, a patient with diabetes who does not wish to receive higher dose glucocorticoids or a patient on MMF or <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> with leukopenia at higher doses), switching to an alternative initial regimen is also an option. As an example, switching from MMF to a <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> regimen, or vice versa, is reasonable.</p><p></p><p class="bulletIndent1">For patients with mild relapsing focal or diffuse LN with a predominance of increased proteinuria, some clinicians would add a low dose of a calcineurin inhibitor if the patient is on MMF or <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>. The use of calcineurin inhibitors in combination with MMF for focal or diffuse LN is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Calcineurin inhibitors plus mycophenolate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse after discontinuation of therapy</strong> – For patients who develop a mild relapse after discontinuation of immunosuppressive therapy, we suggest reinstitution of the prior subsequent therapy regimen in combination with a short course of glucocorticoids, rather than switching to an alternative subsequent therapy regimen. (See  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Dosing and duration of subsequent therapy'</a>.)</p><p></p><p class="bulletIndent1">As an example, in a patient who previously received <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> for initial and subsequent therapy, mycophenolate can be readministered using the same dose as before discontinuation.</p><p></p><p>There are no data to guide the optimal treatment of a patient with a mild relapse of diffuse or focal LN, and our approach is largely based upon clinical experience and observational data.</p><p class="headingAnchor" id="H1766265430"><span class="h3">Moderate to severe relapse</span><span class="headingEndMark"> — </span>Moderate to severe relapse is generally defined as an active urine sediment and a greater increase in proteinuria (eg, greater than 50 percent), and sometimes with a rise in serum creatinine. These manifestations may be accompanied by a flare in extrarenal manifestations of systemic lupus erythematosus (SLE).</p><p>The approach to the management of moderate to severe relapse varies among clinicians, as there is no high-quality evidence to guide the optimal therapy of such patients. Our approach is as follows  (<a class="graphic graphic_algorithm graphicRef133201" href="/z/d/graphic/133201.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy for relapse</strong> – For most patients with moderate to severe relapse, we suggest reinstitution of the same initial therapy that was used to achieve a clinical response, rather than switching to a different initial therapy regimen. Exceptions include patients who have received multiple prior courses of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> for whom there is concern for cumulative toxicity or risk of infertility; in such patients, it may be preferable to use a mycophenolate-based initial therapy regimen. Patients who are not able to reliably adhere to oral medication regimens may have improved adherence if treated with intravenous cyclophosphamide.</p><p></p><p class="bulletIndent1">Alternatively, some clinicians might choose to modify the initial therapy regimen rather than restart the previous initial therapy regimen. As an example, if a patient relapsed while on MMF alone for initial therapy, treating with MMF plus either a calcineurin inhibitor (<a class="drug drug_general" data-topicid="130589" href="/z/d/drug information/130589.html" rel="external">voclosporin</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>) or <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">belimumab</a> would be reasonable options for initial therapy after relapse. (See  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Initial therapy with mycophenolate or cyclophosphamide'</a> and  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Combination regimens'</a>.)</p><p></p><p class="bulletIndent1">The duration of initial therapy that is used during a relapse depends upon the clinical response. If reinstitution of initial therapy results in relatively rapid clinical improvement within four to six weeks, then it may be reasonable to shorten the duration of therapy provided that careful attention is paid to clinical parameters of disease activity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent therapy for relapse</strong> – Once the course of initial therapy is completed and the patient has achieved a complete or partial response, the patient is continued on subsequent therapy. For most patients with moderate to severe relapse who have achieved a complete or partial response to initial therapy, we suggest using the same regimen as was previously used for subsequent therapy. This includes patients who were identified as being nonadherent to subsequent therapy at the time of relapse, provided that intolerance to treatment was not the reason for nonadherence and that patients are confident they have developed new strategies that will enable them to adhere to those therapies.</p><p></p><p class="bulletIndent1">However, some clinicians choose to modify the subsequent therapy regimen in patients whose relapse occurred while on the original course of therapy. As an example, if a patient relapsed while on MMF alone for subsequent therapy, treating with MMF plus either a calcineurin inhibitor (<a class="drug drug_general" data-topicid="130589" href="/z/d/drug information/130589.html" rel="external">voclosporin</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>) or <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">belimumab</a> would be a reasonable choice. Alternatively, some clinicians might try MMF plus <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. (See  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Dosing and duration of subsequent therapy'</a> and  <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>.)</p><p></p><p>Most trials on remission induction in patients with focal or diffuse LN do not distinguish between those patients treated for a new or relapsing presentation of their disease, and the evidence for new or relapsing disease comes from the same studies. These data are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Initial therapy with mycophenolate or cyclophosphamide'</a> and  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Choice of subsequent therapy'</a>.)</p><p>The interest in the role of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, a B cell-depleting chimeric monoclonal antibody, was largely based on observational data that suggested improved clinical response in patients with LN [<a href="#rid23">23-29</a>]. However, this effect has not been supported by clinical trials. In the multinational Lupus Nephritis Assessment with Rituximab (LUNAR) study, 144 patients with class III or class IV LN were randomly assigned to receive intravenous placebo or rituximab and were followed for 52 weeks; all patients also received MMF [<a href="#rid30">30</a>]. The incidence of complete or partial response was higher with rituximab as compared with placebo (57 versus 46 percent), but this difference was not statistically significant. The frequency of serious infections and hospitalizations, at least over the short term, was similar with rituximab and placebo. One possible explanation for the lack of benefit of rituximab is the small number of patients in this randomized controlled trial. Another possible explanation is the potency of rituximab in depleting peripheral B cells. A post-hoc analysis of the LUNAR trial found that peripheral B cell depletion with rituximab was variable among study participants, and those participants with complete peripheral B cell depletion had a higher renal response at 52 and 78 weeks compared with those who did not [<a href="#rid31">31</a>]. It should be noted, however, that the LUNAR trial was not designed to study the effect of rituximab on relapsing LN.</p><p class="headingAnchor" id="H910123039"><span class="h2">Patients with concurrent lupus membranous nephropathy</span><span class="headingEndMark"> — </span>The treatment approach for patients who relapse and have combined focal or diffuse LN and lupus membranous nephropathy is the same as for patients with relapsing focal or diffuse LN. (See <a class="local">'Approach based on disease severity'</a> above.)</p><p class="headingAnchor" id="H3796465144"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>In addition to requiring additional immunosuppressive therapy, relapses, particularly those with a nephritic sediment, also predict a worse kidney prognosis [<a href="#rid1">1,2,12</a>]. In one report, for example, nephritic relapses (active urine sediment, increase in serum creatinine at least 30 percent above previous baseline, and usually, increased proteinuria) were associated with a marked increase in the rate of a persistent doubling of the serum creatinine at a median follow-up of 10 to 11 years (relative risk was 6.8) [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3746516894"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110740.html" rel="external">"Society guideline links: Systemic lupus erythematosus"</a>.)</p><p class="headingAnchor" id="H3644220091"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of relapse</strong> – Relapse of focal or diffuse lupus nephritis (LN) following an initial response to therapy is primarily defined as recurrent inflammatory activity, usually manifested by any of the following parameters: an active urine sediment (eg, glomerular hematuria with red and/or white blood cell casts, white blood cells in the absence of infection), increased urine protein excretion, and/or an increased serum creatinine. Relapses occur in as many as one-third of patients during follow-up of up to 10 years and may occur while on immunosuppressive therapy or after reduction or discontinuation of therapy. (See <a class="local">'Definition of relapse'</a> above and <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for relapse</strong> – Regular, indefinite follow-up and monitoring is needed for all patients with focal or diffuse LN, even for those in complete clinical response for several years. We monitor patients every three to four months to assess for relapse and determine whether the patient is experiencing toxicity from therapy. (See <a class="local">'Monitoring for relapse'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis of relapse</strong> – The diagnosis of a relapse of diffuse or focal LN is largely clinical and based on the presence of recurrent inflammatory activity, usually manifested by any of the following parameters: an active urine sediment (eg, glomerular hematuria with red and/or white blood cell casts, white blood cells in the absence of infection), increased urine protein excretion, or an increased serum creatinine in the absence of an alternative diagnosis. An increase in anti-dsDNA antibody levels and/or a decrease in serum complement levels are also supportive of a diagnosis of relapse. A kidney biopsy is frequently required to verify recurrent active LN rather than nonimmunologic progression of kidney disease or an alternative diagnosis. However, in patients with clinical and serologic findings consistent with active disease, a biopsy may not be necessary, particularly if the results are unlikely to alter therapy. (See <a class="local">'Diagnosis of relapse'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The treatment of relapsing focal or diffuse LN depends upon the initial immunosuppressive regimen and the severity and timing of relapse  (<a class="graphic graphic_algorithm graphicRef133201" href="/z/d/graphic/133201.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild relapse</strong> – Mild relapse is defined as increased activity of urine sediment and, possibly, a modest (eg, &lt;50 percent) increase in protein excretion but with a stable serum creatinine.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients who develop a mild relapse while still receiving therapy, we suggest increasing the dose of glucocorticoids and, if possible, increasing the dose of the immunosuppressive agent (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, for those who cannot easily increase the doses of their original immunosuppressive regimen, switching to an alternative initial regimen is also an option.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who develop a mild relapse after discontinuation of immunosuppressive therapy, we suggest reinstitution of the prior subsequent therapy regimen in combination with a short course of glucocorticoids, rather than switching to an alternative subsequent therapy regimen (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Mild relapse'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate to severe relapse</strong> – Moderate to severe relapse is generally defined as an active urine sediment and a greater increase in proteinuria (ie, &gt;50 percent), often with a rise in serum creatinine.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients with moderate to severe relapse, we suggest reinstitution of the same initial therapy that was used to achieve a clinical response, rather than switching to a different initial therapy regimen (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Exceptions include patients who have received multiple prior courses of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> for whom there is concern for cumulative toxicity or risk of infertility; in such patients, it may be preferable to use a mycophenolate-based initial therapy regimen.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients with moderate to severe relapse who have achieved a complete or partial response to initial therapy, we suggest using the same subsequent therapy regimen as was previously used for subsequent therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This includes patients who were identified as being nonadherent to subsequent therapy at the time of relapse, provided that intolerance to treatment was not the reason for nonadherence and that patients are confident they have developed new strategies that will enable them to adhere to those therapies. However, some clinicians choose to modify the subsequent therapy regimen in patients whose relapse occurred while on the original course of therapy. (See <a class="local">'Moderate to severe relapse'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46:995.</a></li><li><a class="nounderline abstract_t">Moroni G, Quaglini S, Maccario M, et al. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50:2047.</a></li><li><a class="nounderline abstract_t">Hebert LA, Dillon JJ, Middendorf DF, et al. Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. Am J Kidney Dis 1995; 26:432.</a></li><li><a class="nounderline abstract_t">Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121.</a></li><li><a class="nounderline abstract_t">Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16:1076.</a></li><li><a class="nounderline abstract_t">Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971.</a></li><li><a class="nounderline abstract_t">Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:1886.</a></li><li><a class="nounderline abstract_t">Tamirou F, D'Cruz D, Sangle S, et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 2016; 75:526.</a></li><li><a class="nounderline abstract_t">El Hachmi M, Jadoul M, Lefèbvre C, et al. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 2003; 12:692.</a></li><li><a class="nounderline abstract_t">Ligtenberg G, Arends S, Stegeman CA, de Leeuw K. Predictors of renal flares and long-term renal outcome in patients with lupus nephritis: results from daily clinical practice. Clin Exp Rheumatol 2022; 40:33.</a></li><li><a class="nounderline abstract_t">Grootscholten C, Berden JH. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol Dial Transplant 2006; 21:1465.</a></li><li><a class="nounderline abstract_t">Sidiropoulos PI, Kritikos HD, Boumpas DT. Lupus nephritis flares. Lupus 2005; 14:49.</a></li><li><a class="nounderline abstract_t">Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57:258.</a></li><li><a class="nounderline abstract_t">Mosca M, Bencivelli W, Neri R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int 2002; 61:1502.</a></li><li><a class="nounderline abstract_t">Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006; 21:1541.</a></li><li><a class="nounderline abstract_t">Swaak AJ, van den Brink HG, Smeenk RJ, et al. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. Lupus 2001; 10:51.</a></li><li><a class="nounderline abstract_t">Mok CC, Ying KY, Tang S, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50:2559.</a></li><li><a class="nounderline abstract_t">Sprangers B, Monahan M, Appel GB. Diagnosis and treatment of lupus nephritis flares--an update. Nat Rev Nephrol 2012; 8:709.</a></li><li><a class="nounderline abstract_t">ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990; 33:634.</a></li><li><a class="nounderline abstract_t">West CD. Relative value of serum C3 and C4 levels in predicting relapse in systemic lupus erythematosus. Am J Kidney Dis 1991; 18:686.</a></li><li><a class="nounderline abstract_t">Chagnac A, Kiberd BA, Fariñas MC, et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989; 84:922.</a></li><li><a class="nounderline abstract_t">Cheigh JS, Kim H, Stenzel KH, et al. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis 1990; 16:189.</a></li><li><a class="nounderline abstract_t">Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2013; 28:106.</a></li><li><a class="nounderline abstract_t">Melander C, Sallée M, Trolliet P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009; 4:579.</a></li><li><a class="nounderline abstract_t">Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007; 66:1259.</a></li><li><a class="nounderline abstract_t">Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009; 61:482.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009; 18:767.</a></li><li><a class="nounderline abstract_t">Turner-Stokes T, Lu TY, Ehrenstein MR, et al. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) 2011; 50:1401.</a></li><li><a class="nounderline abstract_t">Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62:2458.</a></li><li><a class="nounderline abstract_t">Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64:1215.</a></li><li><a class="nounderline abstract_t">Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. Clin J Am Soc Nephrol 2018; 13:1502.</a></li></ol></div><div id="topicVersionRevision">Topic 131335 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11953977" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8943489" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7645551" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209517" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728784" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999109" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sequential therapies for proliferative lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22087680" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25757867" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514132" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33822705" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Predictors of renal flares and long-term renal outcome in patients with lupus nephritis: results from daily clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16644774" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15732288" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lupus nephritis flares.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620207" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11918758" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16455674" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11243510" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15334470" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23147758" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnosis and treatment of lupus nephritis flares--an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2346519" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1962654" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Relative value of serum C3 and C4 levels in predicting relapse in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2760219" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Outcome of the acute glomerular injury in proliferative lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2399912" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22764193" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19261822" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17412738" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19333973" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19578100" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21398661" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20506527" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22231479" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30089664" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
